The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1144
ISSUE1144
November 25, 2002
Ibritumomab Tiuxetan (Zevalin) for Non-Hodgkin's Lymphoma
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Ibritumomab Tiuxetan (Zevalin) for Non-Hodgkin's Lymphoma
November 25, 2002 (Issue: 1144)
Yttrium-90 ibritumomab tiuxetan (Zevalin -IDEC) was approved by the FDA for treatment of patients with relapsed or refractory low-grade follicular or transformed B-cell non-Hodgkin's lymphoma (NHL), including patients with follicular lymphoma...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.